Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Teva Pharmaceuticals has launched its generic Erythromycin tablets in 250 mg and 500 mg strengths, a therapeutic equivalent to Arbor Pharmaceuticals' reference drug. These tablets are used to treat several bacterial infections and prevent rheumatic fever in penicillin-allergic patients. Teva, with a robust portfolio of nearly 550 generic medicines, leads in FDA-approved generics and holds approximately 100 first-to-file opportunities. Annual sales for Erythromycin in the U.S. exceed $49 million, indicating significant market potential for Teva's new offering.

Teva Pharmaceuticals announced new data from a 3-year study of AUSTEDO^® (deutetrabenazine) for tardive dyskinesia (TD), to be presented at the 2021 APA Virtual Annual Meeting (May 1-3). This study investigates long-term safety, quality of life (QoL), and patient outcomes in 337 patients. Results show that 79.8% reported at least one adverse event, with low incidence rates. QoL improvements were noted with significant scores change over 145 weeks. AUSTEDO is indicated for both TD and chorea associated with Huntington’s disease.

Teva Pharmaceuticals has launched the first generic isotretinoin capsules (10 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg) in the U.S. for treating severe nodular acne in non-pregnant patients aged 12 and older. This introduction adds to Teva's robust portfolio, which includes over 550 generic medicines. Isotretinoin capsules, with annual sales exceeding $158 million, offer an essential option for patients unresponsive to conventional therapies. Teva's generics division continues to lead in first-to-file opportunities, further solidifying its market presence.

Teva Pharmaceutical Industries Ltd. (TEVA) reported Q1 2021 revenues of $3,982 million, a 9% decline from Q1 2020. Profitability improved, with net debt reduced to $23.2 billion. Key products like Truxima® and AUSTEDO® showed growth, while COPAXONE revenues fell significantly in both North America and Europe. GAAP net income increased to $77 million, with EPS at $0.07. However, non-GAAP net income dropped to $699 million and diluted EPS to $0.63, reflecting a 12% decrease in adjusted EBITDA. Teva maintains a financial leverage of 69%.

Teva Pharmaceuticals announced four new posters on long-term analyses of AUSTEDO (deutetrabenazine) at the 2021 American Psychiatric Association Annual Meeting occurring May 1-3, 2021. These studies focus on long-term efficacy, safety, and quality of life improvements in patients with tardive dyskinesia. Notable findings from pivotal trials and a three-year open-label study will be shared, highlighting patient-centered outcomes. Teva aims to enhance understanding of mental health challenges and the role of AUSTEDO in treatment.

Teva Pharmaceuticals has launched a 1000 mg generic version of Casana® (mesalamine) suppository for treating active ulcerative proctitis in the U.S. This medication addresses the needs of approximately 1 million individuals affected by ulcerative colitis. Teva holds a prominent position in the generics market, with around 550 approved products and 100 pending generic applications. Annual sales of mesalamine suppositories exceed $74 million in the U.S. This release underscores Teva's commitment to providing affordable treatment options.

Teva Pharmaceuticals announced new data on AJOVY (fremanezumab-vfrm) at the 2021 AAN Virtual Annual Meeting. The data includes 17 posters spanning long-term response in patients who initially did not respond to treatment and real-world treatment patterns. Approximately 50% of inadequate responders achieved a 50% reduction in monthly migraine days by month 15. Additionally, the study demonstrated significant reduction in acute medication claims associated with AJOVY, indicating improved treatment adherence. AJOVY remains the only long-acting anti-CGRP subcutaneous injection approved for migraine prevention in adults.

Teva Pharmaceuticals USA announced 19 presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting from April 17-22. These include data on AJOVY^® (fremanezumab) and AUSTEDO^® (deutetrabenazine). The findings emphasize AUSTEDO's safety in treating tardive dyskinesia and Huntington's disease, while AJOVY's data highlight long-term treatment efficacy. Denisa Hurtukova, VP of North America Medical Affairs, stated the commitment to enhancing patient lives with informed treatment decisions.

Teva Canada has launched a new autoinjector for AJOVY® (fremanezumab), enhancing the preventive treatment of migraines for adults experiencing at least four migraine days monthly. Previously available only in a prefilled syringe, AJOVY® now offers two latex-free formats: an autoinjector and a syringe, with flexible dosing options (225 mg monthly or 675 mg quarterly). This positions AJOVY® as the first anti-CGRP drug in Canada with multiple delivery methods. The device features a button-free mechanism and is designed for one-time use, supporting patients' needs for choice in migraine management.